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Abstract
Multiple myeloma (MM) is a lethal human cancer characterized by a clonal expansion of malignant plasma cells in bone
marrow. Mouse models of human MM are technically challenging and do not always recapitulate human disease. Therefore,
new mouse models for MM are needed. Mineral-oil induced plasmacytomas (MOPC) develop in the peritoneal cavity of oil-
injected BALB/c mice. However, MOPC typically grow extramedullary and are considered poor models of human MM. Here
we describe an in vivo-selected MOPC315 variant, called MOPC315.BM, which can be maintained in vitro. When injected i.v.
into BALB/c mice, MOPC315.BM cells exhibit tropism for bone marrow. As few as 104 MOPC315.BM cells injected i.v. induced
paraplegia, a sign of spinal cord compression, in all mice within 3–4 weeks. MOPC315.BM cells were stably transfected with
either firefly luciferase (MOPC315.BM.Luc) or DsRed (MOPC315.BM.DsRed) for studies using noninvasive imaging.
MOPC315.BM.Luc cells were detected in the tibiofemoral region already 1 hour after i.v. injection. Bone foci developed
progressively, and as of day 5, MM cells were detected in multiple sites in the axial skeleton. Additionally, the spleen (a
hematopoietic organ in the mouse) was invariably affected. Luminescent signals correlated with serum myeloma protein
concentration, allowing for easy tracking of tumor load with noninvasive imaging. Affected mice developed osteolytic
lesions. The MOPC315.BM model employs a common strain of immunocompetent mice (BALB/c) and replicates many
characteristics of human MM. The model should be suitable for studies of bone marrow tropism, development of osteolytic
lesions, drug testing, and immunotherapy in MM.
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Introduction
Recent progress in unraveling the biology of MM, particularly
the intracellular signaling pathways and the interactions with the
bone marrow microenvironment, has resulted in development of
novel targeted therapy [1]. Different animal models for MM
disease have contributed to this progress, each model having
advantages and disadvantages in this respect.
Xenograft models using human myeloma cell lines, or primary
human myeloma have been established in immunodeficient SCID
or NOD scid gamma (NSG) mice[2–8]. In particular, models have
been generated where human MM cells grow in human fetal bone
transplants in immunodeficient SCID mice [9]. More recently
three-dimensional bone-like scaffolds were coated with mouse or
human bone marrow stromal cells and implanted under the skin of
SCID mice. Subsequently, injection of purified primary myeloma
cells into these scaffolds gave rise to tumor formation that could be
followed by measuring myeloma protein concentration [10].
Although these models allow experiments of human MM cells
in vivo in mice, the models are demanding and not completely
physiological.
Mouse models where MM cells can be transferred between
syngeneic mice are also available. However, mouse MM models
do not necessarily accurately reflect human disease. MM-like
disease arises spontaneously in aged C57BL/KaLwRij mice[11–
13]. The 5T2MM and the 5T33MM cell lines were established
from such mice, and have been extensively used for studying
homing mechanisms of MM cells to bone marrow, interaction of
MM cells with the bone marrow environment, and evaluation of
new therapies [14]. Both models are characterized by MM cell
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infiltration restricted to bone marrow and spleen (a hematopoietic
organ in mice) [15]. The 5T2MM model, but not 5T33MM, is
associated with an extensive osteolysis, seen on plain radiographs
of femur and tibia[15–16]. Both 5T2MM and the 5T33MM are
maintained by in vivo passages and cells die after 24 to 48h in
culture. However, two in vitro growing subclones of the 5T33MM
model have been developed, namely the 5T33MMvt [17] and the
5TGM1 cells [18]. Intravenous injection of 5TGM1 cells give rise
to MM-like osteolytic disease. 5TGM1 cells have also been labeled
with luciferase [19] and green fluorescent protein (GFP) [20], and
used for in vivo imaging of MM-like disease. A major drawback of
the 5TMM models is the dependency on a particular mouse strain
(C57BL/KaLwRij) of limited availability.
Finally, three different transgenic mice models have recently
been developed based on double-transgenic Myc/Bcl-XL mice
[21], the activation of MYC under the control of a light chain gene
[22], or cloning of a spliced form of mouse XBP-1 downstream of
the immunoglobulin VH promoter and enhancer elements [23].
Although they recapitulate several characteristics of MM, these
models are time-consuming and costly, perhaps explaining their
limited use thus far.
In summary, the available MM models presented above can be
technically challenging and require large investments. Thus, there
is a need for an MM model where MM cells can be grown in vitro
and when i.v. injected in a common laboratory inbred mouse
strain, such as BALB/c, faithfully duplicate the major character-
istics of MM disease seen in patients.
Plasmacytomas can be experimentally induced in certain strains
of mice by i.p. injection of mineral oil, adjuvants and alkanes [24].
Such mineral oil-induced plasmacytomas (MOPC) can be serially
transplanted s.c. or i.p. and have been extensively used in tumor
immunological studies[25–30]. However, these plasmacytomas
typically grow locally at the site of injection, and only infrequently
metastasize to the bone marrow[31–33]. Due to their local growth,
it has been questioned if MOPC tumors represent good models for
human MM that primarily affects bone marrow.
We have previously described an in vivo-selected variant of
MOPC315, MOPC315.4, which efficiently forms local tumors
after s.c. injection [34]. We here show that repeated i.v. injections
of MOPC315.4 cells, followed by isolation of tumor cells from
femurs between passages, enriches for a stable variant
(MOPC315.BM) that can be grown in vitro, has tropism for bone
marrow after i.v. injection, and causes osteolytic lesions. Spatio-
temporal development of disease may be monitored by serial and
noninvasive measurement of the bioluminescent signal of lucifer-
ase-labeled cells.
Results
A Multiple Myeloma-like Cell Line, MOPC315.BM, which
Homes to and Expands in the Bone Marrow after i.v.
Injection
Previously, an in vitro-adapted MOPC315 cell line from ATCC
(TIB23) was passaged s.c. twice to obtain a variant, MOPC315.4,
that consistently produced s.c. extramedullary plasmacytomas
[34]. This cell line has been extensively used in tumor
immunological studies[26–30]. To obtain a MM-like variant cell
line with tropism for the bone marrow, MOPC315.4 cells were
injected i.v. at a high dosage (26106). Tumor cells were flushed
from femurs of the first mouse that developed paraplegia, a sign of
spinal cord compression. This procedure was repeated 9 times
(Fig. 1A). The final cell line, MOPC315.BM, was compared with
MOPC315.4 and MOPC315 (ATCC) in tumor challenge
experiments in which the same number of in vitro-cultured cells
Figure 1. The development and tumorigenicity of
MOPC315.BM. (A) The historic line of development of MOPC315.BM
in senior author’s lab. (B) BALB/c mice were injected i.v. with
MOPC315.BM, MOPC315.4 or MOPC315 (ATCC) (26105, n = 12/group).
All mice developed at the endpoint paraplegia due to spinal cord
compression except two mice injected with MOPC315 (ATCC) that
reached the endpoint by weight loss. One mouse (") injected with
MOPC315 (ATCC) did not develop tumor disease at all. The survival
curves are significantly different, both for MOPC315.BM compared to
MOPC315.4 (*p,0.0001) and MOPC315.4 compared to MOPC315
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(26105) were injected i.v. (Fig. 1B). Tumor development was
monitored by serial measurements of M315 myeloma protein in
serum (Fig. 1C, Fig. S1A). The endpoints were defined as 1)
paraplegia, 2) visible extramedullary tumor growth with tumor size
.1 cm in diameter, 3) distended abdomens, or 4) weight loss
.10%.
All mice injected with MOPC315.BM cells developed paraple-
gia within 30 days. Paraplegia was also induced by MOPC315.4,
but disease development was delayed by about 14 days compared
to MOPC315.BM. The ATCC line was slowest at causing spinal
involvement, moreover, 2 out of 12 mice died of tumor disease but
without paraplegia, and one mouse did not develop tumor disease
at all (Fig. 1B). Consistent with these results, mice injected with
MOPC315.BM cells had a more rapid increase in serum M315
myeloma protein compared with the other two cell lines (Fig. 1C,
Fig. S1A). Notably, the increase in serum M315 myeloma protein
is more uniform in mice injected with MOPC315.BM, than mice
injected with the MOPC315.4 or the MOPC315 (ATCC) cell
lines. These results establish a hierarchy for the rapidity of spinal
MM disease onset: MOPC315.BM.MOPC315.4.MOPC315
(ATCC).
Next, titrated amounts of MOPC315.BM and MOPC315.4
cells were injected i.v. (Fig. 1D). The results show that the
MOPC315.BM line was more tumorigenic than parental
MOPC315.4 by a factor of ,20. As few as 2000 or 400
MOPC315.BM cells caused paraplegia in respectively 66% and
33% of the mice within 50 days, while as many as 50,000
MOPC315.4 cells were required to cause paraplegia in 17% of
mice within the same time frame. This finding indicates that an
increased fraction of MOPC315.BM cells have the ability to
establish progressive bone marrow disease after i.v. injection,
compared to MOPC315.4.
Given that the MOPC315 cell line after i.v. injection appears to
induce MM-like disease, we tested the sensitivity of
MOPC315.BM to the MM drug bortezomib, a proteasome
inhibitor, in vitro (Fig. S2). The IC50 was 10–15 nM, which is in
the same range as that previously reported for chemosensitive MM
cell lines [35].
Tagging MOPC315.BM Cells with Luciferase Produced a
Cell Line (MOPC315.BM.Luc), with a Delayed Onset of
Paraplegic Disease
MOPC315.BM cells were transfected for constitutive expression
of the firefly luciferase gene (MOPC315.BM.Luc). We first tested if
transfection affected tumor growth. The MOPC315.BM.Luc cells
were considerably slower at inducing paraplegic disease than the
untransfected counterpart (Fig. 2A). This was confirmed by a
delayed increase in serum myeloma protein (Fig. 2B, Fig. S1B).
This finding prompted us to investigate if growth and myeloma
protein secretion differed for the various cell lines in vitro (Table
S1). The results show that MOPC315.BM and the
MOPC315.BM.Luc cells grow at nearly equal rates and faster
than both MOPC315 (ATCC) and MOPC315.4. For unknown
reasons, MOPC315.BM.Luc secreted higher amounts of M315
myeloma protein than the other three cell lines. Based on these
results, it appears likely, but not proven, that the slow kinetics of
disease development of MOPC315.BM.Luc compared to
MOPC315.BM in BALB/c mice is due to a low level immuno-
genicity to luciferase, resulting in slower growth but not
elimination of luciferase-marked cells.
Spatiotemporal Monitoring of MM Disease using
MOPC315.BM.Luc Cells by Bioluminescence Imaging (BLI)
In MOPC315.BM.Luc-injected mice, tumor burden and
localization could be detected by use of a CCD camera (IVIS
Spectrum), as previously described in other tumor models [36].
Repetition of this noninvasive procedure throughout the course of
the experiment resulted in a spatiotemporal resolution of tumor
development in single animals.
When 26105 cells were injected in BALB/c mice, signals were
detected by day 10 and increased progressively (Fig. 2C,E,F). With
time, signals from individual foci (Fig. 2C) and the overall signals
(Fig. 2F) increased in strength, and an increasing number of foci
could be detected (Fig. 2C,G). Typical sites of bone affection were
spine = femur.shoulder region.sternum (Fig. 2D,G). In addition,
signals were frequently seen corresponding to the hip region, but
in BALB/c mice the level of resolution was not sufficient to
pinpoint localization. Signals from the spleen were present in
100% of mice (Fig. 2G), while signals from other internal organs
including liver were rarely detected.
Bioluminescence is a Valid Measurement for Tumor Load
in BALB/c Mice
In the experiment of Fig. 2, both luminescence and serum
myeloma protein were followed over the course of the experiment.
The results show that the bioluminescence signals correlated with
M315 serum concentrations in single mice (Fig. 2H, r = 0.8929,
p,0.001). Moreover, the two methods for assessment of tumor
load have approximately the same sensitivity although the data
indicate that measurement of myeloma protein in an idiotype-
specific ELISA is slightly more sensitive. A significant biolumines-
cent signal was definitely reached when myeloma protein
concentration exceeded 100 ng/ml. Because serum myeloma
protein concentration is considered to be a gold standard for
tumor load in MM, one may conclude that the strength of the
bioluminescence signal is a valid measurement for tumor size.
BLI and CT of BALB/c nu/nu Mice: Monitoring Tumor
Growth and Localization to the Axial Skeleton
To increase sensitivity of detection, MOPC315.BM.Luc cells
were injected i.v. at a higher dose (56106) and into BALB/c nu/
nu which lack hair and are thus better suited for BLI and the 3D
bioluminescence imaging technique Diffuse Luminescent Imaging
Tomography (DLIT). Immediately after injection, cells were
clearly observed in the lung region in all mice injected. Most
importantly, a weak signal, 5–10 fold higher than the correspond-
ing region of the control mice, could be observed in the
tibiofemoral region already 1h after injection (Fig. 3B). Such
tibiofemoral signals were observed in 14 out of 14 mice, average
photons detected were 1.3610565.46103 SD versus
1.9610362.46102 SD for non-injected controls (p,0.0001),
indicating that tumor cells had entered the bone marrow
immediately after injection. On day 2, the signal from the lungs
had disappeared and a very weak signal was located in the spleen
and the liver. By day 5, signals were found in multiple foci in
bones, primarily the femurs, the lower part of the spine, and the
(ATCC) (**p = 0.0043). (C) Serum myeloma protein M315. At day 10,
M315 levels for MOPC315.BM were significantly different from
MOPC315 and MOCP315.4 (p,0.0001). At day 20 and 30, M315 levels
for all three cell lines were significantly different from each other
(p,0.003). One mouse (") did not develop detectable levels of M315,
this being the same mouse that did not develop tumor disease as
shown in A. Data are presented as mean 6 SD in Fig. S1. N.D. =Not
Detected. (D) Titration of MOPC315.BM and MOPC315.4 by i.v. injection
and development of paraplegia (n = 3–6/group).
doi:10.1371/journal.pone.0051892.g001
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hip. Tumor development was followed by BLI until the mice
developed paraplegia (Fig. 3A,C,D) (average time for endpoint was
33 days, n = 14, Fig. S3A). As may be seen, the average
luminescence signal decreased on day 2 and 5 to about 8% of
immediate post-injection values, and recovered to initial levels
between days 8 and 10 (Fig. 3D). This indicates that a substantial
number, perhaps 90%, of cells may die in the days following i.v.
injection. Progressive tumor growth was confirmed by increasing
levels of myeloma protein in sera (Fig. S3B). Luminescence signals
were highly correlated with serum M315 levels (Fig. 3E,
r = 0.9648, p,0.0001). At onset of paraplegia, when the lumines-
cence signal usually was strongest (see Fig. 3C for a typical
example), DLIT and CT were performed on individual mice.
Tumor tissue and the axial skeleton were co-localized in 3D
(Fig. 3F). To confirm that the luminescence signal was in fact
emanating from the skeleton, individual bones were dissected, or
only skin was removed, before performing high resolution BLI, to
more clearly expose skeletal sites (Fig. 3G–J). This procedure
enhanced sensitivity, and individual foci could clearly be seen in
spine (Fig. 3G), ribs (Fig. 3H), sternum (Fig. 3I) and femur and
tibia (Fig. 3J). The strong signal emanating from the lower spine in
most mice (e.g. Fig. 3A,C,F,G) is compatible with early occurrence
of paraplegia due to compression of the spinal cord in diseased
mice. In addition, internal organs were dissected and analyzed by
BLI (Fig. 3K–O). A strong signal was observed from the spleen
and much lower signals from other organs. Co-localization of
tumor and axial skeleton is further demonstrated in two videos (full
mouse in Fig. S4 and close-up in Fig. S5). Note that a strong signal
corresponding to the spleen was observed, but no signals from
other organs.
MOPC315.BM Cause Disease Primarily in the Bone
Marrow
On autopsy, all paraplegic BALB/c mice injected with
MOPC315.BM had visible tumor growth in spleens (a hemato-
poietic organ in the mouse), resulting in splenomegaly, but more
rarely in the liver and other organs. It was macroscopically difficult
to determine bone disease in paraplegic mice, even though visible
tumors were sometimes seen penetrating the cortical bone. By
microscopic analysis of H&E-stained sections, tumor growth was
routinely found in bone marrow of femurs (Fig. 4A) and in spleens
(Fig. 4B), as well as infrequently in the livers, fallopian tubes and
subcutaneous tissues (Fig. S6). Immunohistochemistry demonstrat-
ed that MM cells expressed lambda and not kappa Ig L chains
consistent with MOPC315 producing IgAl2 myeloma protein
(Fig. 4A,B).
Fluorescent Protein (DsRed)-labeled MOPC315.BM Cells
Preferentially Home to the Bone Marrow
To confirm the presence of MOPC315.BM cells in the bone
marrow and spleen, we transfected MOPC315.BM with DsRed,
and injected cells i.v. into C.B-17 SCID mice. Upon onset of
Figure 2. Delayed growth and BLI of Luciferase-transfected
MOPC315.BM-cells. (A) Tumor take experiment with MOPC315.BM.-
Luc (26105 cells i.v.) (n = 13) was overlaid that of MOPC315.BM shown in
Fig. 1B (also 26105 cells i.v.). The survival curves showing development
of paraplegia are significantly different (p,0.0001). (B) Levels of M315
myeloma protein in sera of mice in (A). M315 was significantly different
at day 10, 20 and 30 (p,0.002). N.D. =Not Detected. (C–E) All scales in
photons/second/cm2/steradian. (C) Timeline of bioluminescent signals
in a representative BALB/c mouse injected with 2.06105 MOPC315.BM.-
Luc i.v. (D) Examples of typical sites of affection. I: sternum, femurs,
spleen. II, III: spine, femurs, spleen. IV: spine, femurs, spleen, shoulder.
(E) Tumor growth of MOPC315.BM.Luc in four representative BALB/c
mice pictured at day 28. (F) Luminescence emitted from typical sites of
growth as a function of time (n = 13). MOPC315.BM.Luc mice (open
boxes) are compared to non-injected control mice (filled boxes).
*p,0.031 for femur and spine. **p,0.04 for all indicated sites. (G)
Frequency of tumor growth in various sites on day 10, 21 and 31.
*Signals from the shoulder region could not be attributed to particular
bones. (H) Correlation of serum myeloma protein M315 measured on
days 10, 21 and 32 and average luminescence [radiance (photons/
second/cm2/steradian)] emitted in individual mice (r = 0.8929, p,0.001).
doi:10.1371/journal.pone.0051892.g002
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paraplegia, femurs and spleens were analyzed by flow cytometry
(Fig. 5A) and femurs by immunohistochemistry (Fig. 5B) for the
presence of MOPC315.BM.DsRed cells. For all injected mice
(n = 3), DsRed positive cells were detected in bone marrow flushed
from femurs. Cells were also detected in the spleen (Fig. 5A).
MOPC315.BM.DsRed cells were present in the extravascular
space of femur bone marrow, as shown by microscopy of H&E
stained sections from paraffin-embedded tissue (Fig. 5B). These
results essentially confirm the conclusions of Luciferase-based
whole body imaging, and support a bone marrow-tropism of the
MOPC315.BM cell line.
MOPC315.BM.Luc Injected Mice Develop Osteolytic
Lesions
Osteolysis is a hallmark of human MM. Mice with growth of
MOPC315.BM.Luc cells in bone marrow developed osteolytic
lesions by several criteria. Firstly, MOPC315.BM.Luc induced an
increased number of TRAP+ osteoclasts, compared to control
mice injected with RPMI 1640 tissue culture medium (Fig. 6).
Secondly, transmission X-rays demonstrated osteolytic lesions of
femurs (Fig. 7A,B) and tibiae (data not shown), which were
confirmed by mCT (Fig. 7C,D). In addition, severity of osteolytic
lesions was quantified by bone structure analysis via mCT (Fig. 7E-
J, Fig. S7). Osteolysis was evident in mice 5–8 weeks after injection
of MOPC315.BM.Luc (Fig. 7E–J) as well as in mice with
Figure 3. Co-localization of tumor cells and axial skeleton in MOPC315.BM.Luc injected in BALB/c nu/nu mice. (A) A photomontage of
three representative BALB/c nu/nu mice (out of 14) serially imaged from day 0 to day 25. For days 0–8, the color scale was set at a radiance (photons/
second/cm2/steradian) of 104 to105 (F stop 1, exposure 60 seconds or autoexposure 104 counts, binning 8). From day 10 to 25 the scale was set at a
radiance of 105 to106. (F stop 1, exposure 60 seconds or autoexposure 104 counts, binning 1). (B, left picture) Ventral view of 3 mice injected 1h
previously, showing weak signals emanating from the tibiofemoral regions. Such signals were consistently detected in 14/14 mice 1–2.5h after i.v.
injection. Color scale was set at a radiance (photons/second/cm2/steradian) of 104 to105. (B, right picture) A close-up of the region of interest
indicated by the red circle. (C) A close-up picture series of one mouse (day 33) showing typical sites of affection (skull, shoulder region, sternum,
spine, femurs, tibia and spleen). The scale was set at a radiance of 105 to106 (F stop 1 autoexposure 104 counts emission filter 620 nm). (D) A graph of
the average luminescence [radiance (photons/second/cm2/steradian)] of BALB/c nu/nu male mice (n = 14) from day 0 to day 25. The luminescence
value for each mouse is the average of ventral, dorsal and lateral (right/left) views. (E) A correlation plot of average luminescence for each mouse
compared to their respective serum M315 values on day 10 (r = 0.9648, p,0.0001). Similar data were obtained on day 20. (F) DLIT and CT of a mouse
with co-localization of tumor signal and the skeleton. The orange spheres depict where signal gradients are located. Pictures of various bones after
removing skin or explanting organs, scales in photons/second/cm2/steradian, (G) spine, (H) ribs, (I) sternum, (J) femur and tibia, (K) kidneys, (L) lungs
and heart, (M) spleen, (N) intestines and (O) liver.
doi:10.1371/journal.pone.0051892.g003
Figure 4. Histology and immunostaining of organs from
paraplegic BALB/c mice injected with 56105 MOPC315.BM
(IgAl2315) cells i.v. (A) Bone marrow. Left: H&E staining. Right:
Immunostaining with anti-l or anti-k (inset) antibodies, developed by
HPRO (brown). (B) Spleen, red pulp. Left: H&E staining. Right:
Immunostaining with anti-l or anti-k (inset) antibodies.
doi:10.1371/journal.pone.0051892.g004
Figure 5. Flow cytometry and histology of MOPC315.BM DsRed
cells injected i.v. in C.B-17 SCID (56106) and BALB/c mice
(16106). (A) Upper left: Flow cytometric histograms of MOPC315.BM
DsRed cells (solid line) and as a control MOPC315.BM cells (dashed line).
Flow cytometry from a representative paraplegic C.B-17 SCID mouse.
Upper right: Femur cells (solid line) and normal femur (dashed line).
Lower right: spleen (solid line) and normal spleen (dashed line). The
average and standard deviations for each organ are shown on each
plot. Backgrounds in a non-injected mouse (to the right of the vertical
line) were for femur 1.34% and spleen 1.68%. (B) I: H&E staining from a
femur of a paraplegic BALB/c mouse. II: Fluorescence microscopy of
sections of same femur. III: Femur from a mouse injected with non-
fluorescent MOPC315.BM (control).
doi:10.1371/journal.pone.0051892.g005
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paraplegic disease (6–11 weeks after injection; Fig. S7). mCT
assessment of total, trabecular and cortical bone compartments
revealed highly significant changes in mice after injection of
MOPC315.BM.Luc cells as compared to controls. Disturbed
architecture of trabecular bone was demonstrated by decrease of
trabecular number and trabecular thickness, and increase of
trabecular separation (Fig. 7E–G, Fig. S7A–C). Overall bone
volume decreased as evidenced by reduced bone volume fraction
and an increased ratio of bone surface to bone volume (Fig. 7H–I,
Fig. S7D–E). Moreover, the total mineral density was significantly
reduced in MOPC315.BM.Luc injected mice (Fig. 7J, Fig. S7F).
Thirdly, mice injected with MOPC315.BM had increased levels of
calcium (Ca2+) in sera. For unknown reasons, a plateau level of
Ca2+ was obtained by day 20 (Fig. 7K). Taken together, these
results demonstrate that the MOPC315.BM cell line induces
osteolytic lesions, a hallmark of human MM, when delivered by
i.v. injection.
Discussion
We here describe a novel variant of MOPC315,
MOPC315.BM, that after i.v. injection of in vitro-cultured cells
induce MM-like disease in the axial skeleton of syngeneic BALB/c
mice, BALB/c nu/nu, C.B-17 SCID and NSG. Luciferase-labeled
cells (MOPC315.BM.Luc) allow spatiotemporal resolution of bone
disease development by repeated in vivo imaging. Injected mice
develop osteolytic lesions, a hallmark of human MM. This novel
mouse MM model could be useful for studies of bone marrow
tropism, efficacy of drugs, mechanism of osteolysis, and immuno-
therapy. An important aspect of the current MOPC315.BM
model is that experiments can be performed in an immunocom-
petent and readily available laboratory mouse strain, BALB/c. A
further advantage is that the white fur of this albino strain makes
in vivo imaging more sensitive and simpler to perform than in mice
with black fur.
The results demonstrate that a mineral oil-induced plasmacy-
toma, MOPC315 (ATCC), adapted to in vitro growth, can cause
paraplegia in about 80% of mice within 100 days after i.v
injection. This finding was not anticipated since MOPCs are
generally considered to be poor models of MM bone disease, even
though they readily form extramedullary plasmacytomas after
local injection. It may be that MOPC315 has an increased tropism
for bone marrow compared to other MOPC lines and bone
marrow tropism may thereby vary between different MOPC lines.
The results further demonstrate that variants of the MOPC315
(ATCC) cell line can be obtained that more rapidly induces MM-
like bone disease. Thus, a cell line selected for high tumor take by
s.c. injection, MOPC315.4, caused paraplegia in all i.v.-injected
mice within 65 days. After 9 cycles of i.v. injection of MOPC315.4
and recovery of cells from femurs of paraplegic mice, the
MOPC315.BM cell line was obtained that following i.v. injection
caused paraplegia in all mice within 35 days.
It is unclear whether the consecutive s.c. and i.v. selection
procedures resulted in either a gradual change of phenotype or in
a selection of rare cells with more MM-like features, pre-existing in
the parental plasmacytoma cell line. The fact that decreasing
amounts of injected cells were needed with progressive cycles
could indicate that the in vivo-selection might have enriched for a
pre-existing variant. It is also unknown whether preferential
growth in bone marrow was due to increased homing to the bone,
or if cells simply grew better once they had settled in the bone
marrow microenvironment or both.
MOPC315.BM cells labeled with firefly luciferase
(MOPC315.BM.Luc) could be followed by repeated biolumines-
cent imaging of i.v.-injected mice. Overall, the results were similar
in normal BALB/c and T cell-deficient BALB/c nu/nu mice.
However, sensitivity was clearly higher in furless BALB/c nu/nu
mice, the nude strain being the recommended model for DLIT
(Living ImageH User Manual, Caliper Life Sciences). Sensitivity
was further increased by injection of a higher number of cells.
Immediately after injection, cells were found primarily in the lung,
Figure 6. Osteoclasts in bone marrow of NSG mice infiltrated with MOPC315.BM.Luc. (A,B) Representative images of TRAP+ staining from
the bone marrow of an age-matched control NSG mouse injected with RPMI 1640. (C–E) Representative images of TRAP+ staining from the bone
marrow of an NSG animal injected with MOPC315.BM.Luc. Inset in (C) shows bone marrow localization of transplanted MOPC315.BM.Luc cells using
staining for IgA. TRAP+ osteoclasts are indicated by black arrow heads. In all cases scale bar is 200 mm. (F) Quantification of osteoclasts per mm bone
surface. Controls are age-matched RPMI-injected NSG mice.
doi:10.1371/journal.pone.0051892.g006
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but also in the spleen and the liver. However, and importantly, a
minor fraction of cells were found in the tibiofemoral region
already 1 h after injection. Early invasion of bone marrow is
consistent with results obtained with i.v. injection of 51Cr-labeled
5T2MM cells [37]. (However, note that detection of luciferase-
labeled cells by BLI ensures that cells are alive while a detection of
a 51Cr signal does not necessarily guarantee the presence of living
cells). On day 5, progressively growing MM foci were seen in
multiple sites of the axial skeleton, with signals first being detected
in the femurs and the spine. The spleen signal progressed with
time, while lung and liver signals decreased. Affection of other
organs was only infrequently detected. MM growth in spleen is
consistent with extramedullary hematopoiesis in this organ, and is
also found in the 5TMM models [12,14].
A considerable number of the injected cells apparently died
since the total bioluminescence decreased by .90% on day 2, and
only recovered to initial post-injection values after day 8. Since
injection of about 1000 MOPC315.BM cells caused paraplegia in
Figure 7. Osteolysis induced by MOPC315.BM.Luc cells. Transmission X-rays of distal femurs of NSG mice injected with either RPMI 1640 (A) or
MOPC315.BM.Luc (expressing a doxycycline inducible non-functional control shRNA) (B) show extensive osteolytic lesions in the latter (white arrows).
Similarly, mCT 3D reconstruction of the respective NSG femurs demonstrate reduced wall thickness (white arrows) and trabecular structures in bone
marrow infiltrated by MOPC315.BM.Luc (expressing a doxycycline inducible non-functional control shRNA) (D) compared to age-matched controls (C).
(E–J) Quantification of bone structure changes in BALB/c mice 5–8 weeks after injection of MOPC315.BM.Luc (56105 cells) and in age-matched
controls. (K) Measurement of Ca2+ in serum of BALB/c mice at various time points after injection with MOPC315.BM. *p,0.002.
doi:10.1371/journal.pone.0051892.g007
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about 50% of mice, it may be roughly extrapolated that perhaps
only 100 MOPC315.BM cells, surviving the days following i.v.
injection, is sufficient to cause development of MM-like bone
disease.
Even though relatively few bone foci were seen in BALB/c
mice, the increased sensitivity in nude mice, combined with ex vivo
imaging at endpoint, revealed that MM growth was more diffuse
with multiple foci in single ribs and sternum. Consistent with this,
DsRed-labeled MOPC315.BM cells were detected in every flushed
femur of paraplegic mice. The average is consistent with that often
observed in human MM (.10% malignant plasma cells) though
we only measured three paraplegic mice. Note that the endpoint,
paraplegia due to compression of the lower part of the spinal cord,
is observed relatively early in mice injected with MOPC315.BM.
Thus, in absence of paraplegia, much higher numbers of MM cells
in bone marrow of femur might have been reached. Flow
cytometry data show that the infiltration of MOPC315.BM cells in
tibiae equals that of vertebral bodies (data not shown), however
BLI data indicate that the lower vertebrae could have a higher
density of MM cell foci than other bone sites, predisposing for
paraplegia.
A hallmark of human MM is osteolytic lesions. The
MOPC315.BM induced osteolytic lesions were detected by
histology (staining for TRAP+ osteoclasts), transmission X-rays
and mCT of isolated bones, and elevated Ca2+ levels in serum.
Thereby, ex vivo mCT analysis of distal femurs demonstrated highly
significant changes in trabecular and cortical architecture in
MOPC315.BM injected mice compared to controls. However, the
osteolytic lesions were difficult to detect by standard X-rays of
living mice. Again, if mice could have been observed beyond
development of paraplegia, osteolytic lesions might have become
more pronounced.
Lynch and co-workers have previously described that
MOPC315 grown in diffusion chambers i.p. have a preferential
loss of cells which are of plasmacytoid appearance, resulting in
enrichment of cells which secrete less myeloma protein, but have
increased expression of surface BCR [38]. They have also
described a variant, MOPC315S, that when injected i.v. readily
gave rise to splenic tumor foci [39]. The bone marrow-homing
MOPC315.BM appears distinct from these previously described
variants since its production of secreted myeloma protein and
BCR is similar to that of MOPC315.4, and since it has tropism for
bone in addition to spleen.
It is generally believed that MM cells represent malignant
counterparts of plasma cells that at the earlier B cell stage have
been through a germinal center reaction[40–42]. However, it is
unclear where the neoplastic process initially takes place. One
possibility is that MM originates from plasma cells malignantly
transformed within the bone marrow, and that MM cells later
metastasize to other bones. Another possibility is that neoplastic
cells originate in an extramedullary site, and then seed multiple
bones where they are exposed to a microenvironment conducive
to growth. Several pieces of evidence support the latter possibility.
Firstly, MM has been associated with less differentiated clonogenic
precursors found in blood[43–45]. Secondly, extramedullary
plasmacytomas in humans can metastasize to bone [46]. Thirdly,
ileocecal plasmacytoma in an aged gonadectomized mouse [31], as
well as transplanted MOPC tumors [32,33], can metastasize to the
bone marrow. The present data are compatible with the idea that
MM could originate from cells undergoing malignant transforma-
tion outside the bone marrow and that variants with increased
bone marrow tropism seed multiple bones.
It is of great interest to find out why MM cells home to and
grow in the bone marrow. A comparison of MOPC315.BM and
MOPC315.4 at the protein and gene expression levels might offer
clues as to why the former variant more rapidly causes bone
disease. A number of factors could contribute, such as CD44 splice
variants, chemokine and cytokine receptors, integrins, metallo-
proteases, and responsiveness to growth signals in the bone
marrow microenvironment, including cytokines like IL-6 [47]. In a
global approach to this issue, repeated and independent gene
expression profiling of MOPC315.BM and MOPC315.4, and
extensive flow cytometric and cytokine secretion analysis, has
revealed stable differences (H. C. Jodal et al., proposals for further
investigation). In addition, since the MOPC315.BM model was
established in the BALB/c strain it might be possible, by use of
available knock-out mice on this background, to study the
influence of genes on MM cell homing and growth in the bone
marrow.
In summary, MOPC315.BM and the 5TMM tumors [8,12,14]
appear to share the ability to home to the bone marrow and cause
osteolytic lesions. Similar to the 5TGM1 cell line [18], MOPC315
can be cultured in vitro, injected i.v., and causes MM-like disease.
However, the MOPC315.BM has certain advantages for exper-
imental manipulation since we here show that it may be readily
labeled by luciferase or DsRed for tracking by in vivo imaging, and
since it reproducibly causes bone disease in a common strain of
laboratory mice, BALB/c. The model should be valuable for
studying mechanisms of homing of MM cells to bone marrow and
drug treatment. Moreover, since so much is known about idiotype-
specific T cell immunotherapy of s.c. extramedullary MOPC315
plasmacytomas[26–30], the present model should allow the
application of T cell immunotherapy to MM cells in the bone
marrow (Hofgaard and Bogen, proposals for further investigation).
Materials and Methods
Ethics Statement
This study was carried out in accordance with the 3Rs principle.
Experiments were approved by the National Committee for
Animal Experiments (Oslo, Norway), application no. 2153. All
surgery and euthanization was performed under isoflurane (2.5–
5% inhalation) or midazolam and fentanyl (both 5 mg/ml, i.p.
injection) anesthesia, and all efforts were made to minimize
suffering.
Mice
BALB/c, BALB/c nu/nu and C.B-17 SCID mice were
obtained from Taconic (Ry, Denmark). NOD scid gamma
(NSG) were obtained from Charles River (Germany).
The MOPC315.BM Cell Line
MOPC315 [48] was obtained as an in vitro-adapted cell line
from ATCC (Manassas, Virginia). This cell line was cycled
between in vitro culture and in vivo growth s.c.; the resulting cell
line, MOPC315.4, has been used in our previous s.c. tumor
challenge experiments [26,27,34,49]. To obtain a variant of
MOPC315 that homes to the bone marrow and grows in that site,
a large number of MOPC315.4 cells (26106) were injected i.v. into
five BALB/c mice. The first mouse to develop paraplegia was
euthanized, bone marrow cells were flushed from the femurs, and
cultured in RPMI 1640 GlutaMAX (Gibco) supplemented with
1% MEM NEAA 100x (Gibco), 1% sodium pyruvate (Gibco),
0.005% 1M I-thioglycerol (Sigma) solution, 0.03% Gensumycin
40 mg/ml (Sanofi aventis) and 10% fetal bovine serum (Biochrom
AG). Normal bone marrow cells eventually died and the culture
was taken over by expanding MOPC315.4 cells, which were
expanded and injected i.v. into new BALB/c mice. With
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consecutive passages, mice developed paraplegia more rapidly,
and the number of MOPC315.4 cells injected was eventually
reduced to 2.56105. After the third and the ninth passages,
MOPC315.4 was cloned in vitro by limiting dilution, and clones
that grew well and produced M315 myeloma protein were selected
for further use. After 9 passages, the resulting cell line,
MOPC315.BM, was frozen in aliquots.
Labeling of MOPC315.BM with Luciferase and DsRed
Luciferase labeling: MOPC315.BM cells were co-transfected by
electroporation with the pGL3-Control vector containing the
luciferase gene (Promega), and the pcDNA 3.1(+) vector contain-
ing the gene for neomycin resistance (Invitrogen). For DsRed
labeling, MOPC315.BM cells were co-transfected with the
pCMV-DsRed-Express vector (Clontech), and the pcDNA 3.1(+)
vector. Clones with high expression were re-cloned by limiting
dilution, selected for high expression, frozen in aliquots, and used
for tumor challenge experiments.
Tumor Challenges. Measurement of Myeloma Protein
MOPC315 (ATCC), MOPC315.4, MOPC315.BM,
MOPC315.BM.Luc, and MOPC315.BM.DsRed cells were cul-
tured in vitro (37uC, 5% CO2) and harvested when growing
exponentially, then centrifuged (300 g, 7 min) and resuspended in
PBS (Gibco-BRL, Carlsbad CA). Cells were counted and injected
i.v. in the tail vein. Injection dosage used is indicated in the figure
legend or text. Endpoints were 1) paraplegia, 2) visible extramed-
ullary tumor disease with tumor size .1 cm in diameter, 3)
distended abdomens, or 4) weight loss .10%. The mice were
sacrificed on the same day the endpoint was reached. Disease was
verified by measurement of M315 myeloma protein in ELISA
[26].
Whole Body in vivo Imaging of Tumor Cells
Imaging of luciferase activity in vivo was performed essentially as
described [36]. Mice were injected i.p. with D-luciferin (150 mg/
kg body weight) and imaged using either the IVIS Spectrum or
IVIS Spectrum CT imaging systems (Caliper Life Sciences,
Hopkinton, Massachusetts). Images were acquired from 10 to 20
minutes post substrate injection. Data were analyzed using
LivingImageH (Caliper Life Sciences) software. Each image
included a non-tumor bearing control mouse also administered
D-luciferin. Luminescence for each side or region of tumor
bearing mice was quantified using average photons/second/cm2/
steradian, with the respective area on the non-tumor bearing
control mice subtracted. Diffuse Light Imaging Tomography
(DLIT) and Computer Tomography (CT) modes were performed
on an IVIS Spectrum CT (Caliper Life Sciences). For the DLIT
mode, four spectral images were acquired at 580 nm, 600 nm,
620 nm, and 640 nm. Auto exposure was set at 10,000 photons.
Sequence acquisition was performed between 5 and 40 minutes
post i.p. injection of D-luciferin. For CT, the standard one mouse
or medium resolution settings were used.
To increase sensitivity of detection of MOPC315.BM.Luc,
BALB/c nu/nu mice, which lack hair and are thus better suited
for BLI and the 3D bioluminescence imaging technique DLIT,
were used in some experiments (Fig. 3). However, BALB/c nu/nu
mice also lack a thymus and thus T cells, which may affect the
immune response and tumor growth.
Flow Cytometry
DsRed is, in contrast to luciferase, immunogenic in BALB/c
mice, and immunodeficient mice thus have to be used when
injecting DsRed-transfected cells. C.B-17 SCID mice lack both
B and T cells due to a defect in V(D)J recombination. This may
affect tumor growth to some degree as an immune response
towards the tumor cells will be lacking. C.B-17 SCID mice i.v.
injected with MOPC315.BM DsRed cells were followed until
endpoint and then euthanized. Bone marrow was flushed with
complete medium, using a needle and syringe, from femurs.
Spleens were dissected from individual mice and placed in
complete medium. Spleens were then minced with a scissor and
gently pushed through a sieve (Sigma). The cell suspensions
were centrifuged (300 g 7 min), resuspended in erythrocyte lysis
solution (TRIS 17 mM, NH4Cl 140 mM, pH 7.2), then washed
with PBS and thereupon fixed (1% paraformaldehyde (PFA)).
Bone marrow was gently pipetted to obtain a cell suspension,
centrifuged, then resuspended in PBS with 5% BSA, and fixed
in PFA. The samples were run and analyzed on the FL2
channel of a FACSCalibur flow cytometer using Cell Quest
ProTM and WEASEL softwares. To determine the percentage of
tumor cells in a sample, a marker was placed in front of the
negative controls (femur and spleen cells from a normal mouse)
such that .98% of the cells were to the left of that marker.
Using this marker, all cells to the right were judged to be
positive. The mean and standard deviation from three mice
were then calculated. The backgrounds in the negative controls
(percentage of the cells to the right of the marker) are indicated
in the figure legend.
Histochemistry and Microscopy
When MOPC315.BM-injected BALB/c mice developed para-
plegia, samples were taken from limbs, liver, spleen, lungs,
gastrointestinal tract, kidneys and heart, and fixed in 4% PFA
before embedding in paraffin. 5-mm sections throughout the
organs were made with a rotation microtome (Leica RM2135).
One slide was stained with haematoxylin and eosin and two
additional slides were immunostained for light chain kappa and
lambda in order to visualise the MOPC315.BM cells. For
immunostaining, the endogenous peroxydase was quenched by
incubating the slides with a 50-mL methanol, 0.5-mL H2O2 (3%)
(Merck, Darmstadt, Germany) solution for 20 min. Autoclave
heating was used for antigen retrieval by immersing the slides in a
autoclavable tray, containing 5 mL of Target Retrieval Solution
(Dako, Glostrup, Denmark) and 45 mL of deionised water and
autoclaving at 120uC for 10 minutes. Slides were blocked using a
blocking buffer (Universal Blocking Reagent, Bio Genex) to reduce
non-specific background staining. The horseradish peroxydase
coupled anti-mouse lambda and kappa antibodies (Rockland,
Gilbertsville, PA, USA) were incubated for 2 h at room
temperature at a dilution of 1:1000. Chromogenic visualisation
was accomplished through the use of a DAB reaction (3,30-
diaminobenzidine hydrochloride kit; (DAB), Dako), followed by
counterstaining with haematoxylin.
For immunohistochemistry related to Fig. 6, the tissue was fixed
in 4% PFA, decalcified in 10% EDTA (pH 7.4), embedded in
paraffin before being sectioned (4 mm) and rehydrated. After
HEIR (5 mM citrate buffer pH 7), CD138 mAb (Clone 281–2,
BD Pharmingen) and an AP labeled anti-IgA (Sigma, St. Louis,
Missouri) were used to identify MOPC315.BM.Luc cell infiltra-
tion. All sections were analyzed using a Nikon Eclipse E 800, and
digital images processed with AnalySIS Soft Imaging System, or
images were captured using a Nikon Eclipse TE 2000-U with
either a DS-Qi1Mc (5.03) or Dxm1200 digital camera, with NIS-
Elements BR version 3.0 software.
TRAP staining was done according to Acid Phosphatase,
Leukocyte (TRAP) Kit from Sigma (St. Louis, Missouri),
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without HEIR. These sections were then photographed, regions
of bone marked and the osteoclasts counted by three
individuals, then averaged and divided by bone surface length
(mm) (Fig. 6F).
For detection of MOPC315.BM.DsRed cells, femurs were fixed
in 4% PFA, decalcinated, embedded in paraffin, and de-waxed.
Sections were analyzed by fluorescence microscopy (Nikon Eclipse
E 800) or H&E stained and analyzed by light microscopy (Leitz
Dialux), and digital images processed with AnalySIS Soft Imaging
System.
Transmission X-ray and mCT
NSG mice were injected with a MOPC315.BM.Luc clone
which expresses a doxycycline inducible non-functional control
shRNA (Fig. 7A–D). Explanted bones were fixed in 4% PFA and
X-rayed in an experimental mCT facility[50–51] (Fraunhofer
Development Center for X-ray Technology EZRT, Fu¨rth, and
Institute for X-ray Microscopy, University Wu¨rzburg, Germany).
X-ray source from Excillum, using a liquid metal jet (Galinstan,
GaInSn alloy) anode with a 15 mm spot size at 70 kV and 80 Watt.
Images were detected using a Gadolinium oxysulphide scintillator
and a CMOS camera with 6.5 mm pixel size. Isosurface from mCT
data was computed using Image J (version 1.47c) and the BoneJ
plugin (version 1.34) [52].
For bone structure analysis, BALB/c mice were injected with
MOPC315.BM.Luc (Fig. 7E–J, Fig. S7). Total femur length was
measured using digital calipers on freshly isolated bones. At the
distal femur, endocortical contours were drawn for a region with a
height equivalent to 5% of the femur length, beginning at 850 mM
from the growth plate and proceeding proximal. Thresholds of
1891 mg hydroxyapatite (HA)/cm3 were used for distal femur that
is rich in trabecular bone. Total mineral density (TMD), bone
volume, total volume, bone surface, trabecular number, separation
and thickness were studied on excised samples using a desktop
mCT 40 (Scanco Medical AG, Bru¨ttisellen, Switzerland). Femurs
were scanned and images were reconstructed to an isotropic voxel
size of 10.5 mm. All quantitative analyses were performed with the
system’s software (Scanco Eval 6.5–1).
Measurement of Serum Ca2+
Serum Ca2+ was measured using the Calcium Colorimetric Kit
Assay from BioVision (Milpitas, California).
Statistics
The logrank test was used to compare the Kaplan-Meyer
survival plots. Two-tailed Mann-Whitney was used to compare
groups for levels of serum myeloma protein, bioluminescent
radiance, serum Ca2+, bone surface osteoclasts as evaluated by
histology and all quantitative data concerning the mCT and X-
rays. Correlation between levels of M315 antigen and whole body
bioluminescence was determined on the basis of the Spearman’s
correlation coefficient.
Supporting Information
Figure S1 Serum concentrations of M315 from tumor
challenge studies. (A) Shows the same data as in Fig. 1C, but
displayed with mean and SD for each group at the different time
points. Comparison of i.v. injection of 26105 cells of either
MOPC315 (ATCC), MOPC315.4 or MOPC315.BM. n=12/
group. (B) Shows the same data as in Fig. 2B, but displayed with
mean and SD for each group at the different time points.
Comparison of i.v. injection of 26105 cells of MOPC315.BM.Luc
(n= 13) overlaid the data of MOPC315.BM (n= 12) from Fig.
S1A.
(TIF)
Figure S2 Effect of bortezomib on MOPC315.BM cells
tested in vitro in an MTT assay.
(TIF)
Figure S3 Growth of MOPC315.BM.Luc cells in BALB/c
nu/nu mice. (A) Tumor take experiment. (B) M315 concentra-
tion in ng/ml (solid lines of individual mice). Lower detection limit
of 10 ng/ml.
(TIF)
Figure S4 Video of DLIT and CT of a whole BALB/c nu/
nu mouse. Shows the co-localization of MOPC315.BM.Luc and
the axial skeleton. Note the presence of tumor cells in the spleen,
but no other organs.
(AVI)
Figure S5 Close-up video of DLIT and CT of a BALB/c
nu/nu mouse. Shows the co-localization of MOPC315.BM.Luc
and the axial skeleton, as shown as a whole mouse in Fig. S4. Note
the presence of tumor cells in the spleen, but no other organs.
(AVI)
Figure S6 Infrequent examples of microscopically de-
tected MOPC315.BM tumors. As shown in Fig. 2 in paper
version, spleen and bone marrow were almost always affected,
while affection of other organs was rarer. Shown are infrequent
examples of microscopic growth in liver (A) and fallopian tube (B),
and subcutaneous macroscopic growth (C).
(TIF)
Figure S7 Osteolysis induced by MOPC315.BM.Luc at
paraplegia. BALB/c mice were injected with MOPC315.BM.-
Luc (26105 cells) i.v. and distal femurs were analyzed by mCT at
paraplegia (6–11 weeks after injection). Non-injected 10–11 weeks
old BALB/c mice served as controls.
(TIF)
Table S1 In vitro growth rate and in vitro M315
secretion. All cell lines were cultured as previously described
in this article. Cells growing exponentially were then harvested,
counted, resuspended in medium and kept on ice until use. In vitro
growth was estimated by an assay where 8 parallel samples of
50 ml at a concentration of 16105cells/ml (5000 cells) of a cell line
was added to 200 ml of warm medium (37uC) in 8 wells of a 96
well, flat bottom CostarH plate (Corning Inc., USA). After
standard incubation (37uC, 5% CO2) for 48 hours, and while
the cultures were growing exponentially, the dish was placed on
ice and the cells in each well were counted. The website (http://
www.doubling-time.com/compute.php) was used to calculate
doubling times. In vitro M315 secretion was measured by adding
3 parallel samples of 50 ml at a concentration of 16108cells/ml
(56106cells) of a cell line to 200 ml of warmed medium (37uC) in 3
wells of a 24 well, flat bottom CostarH plate and incubated for 1
hour under standard conditions. The cultures were then
immediately centrifugated and supernantants were stored at
270uC. For each well, the M315 concentration was determined
from the mean of two independent M315 ELISAs. The average
secretion rate was obtained using the added cell number (56106).
The unpaired t test was used to calculate p values. *p,0.05
compared to MOPC315 (ATCC) and MOPC315.4. "Significantly
higher than the other cell lines p,0.05.
(PPT)
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